In vivo imaging of glucose consumption and lactate concentration in human gliomas
- PMID: 1637139
- DOI: 10.1002/ana.410310315
In vivo imaging of glucose consumption and lactate concentration in human gliomas
Abstract
Twenty patients with histologically confirmed gliomas were studied with positron emission tomography (PET) and proton magnetic resonance spectroscopy (1H-MRS). PET with 18F-2-fluoro-2-deoxy-D-glucose (FDG) provided tomograms of the metabolic rate of glucose. MRS images were obtained by combining volume-selective excitation with phase-encoded acquisition. With 32 x 32 gradient phase-encoding steps, an in-plane resolution of 7 x 7 mm was achieved. From this set of spectra, lactate maps were created and compared with PET maps of glucose metabolism. Maximum glucose metabolic rates within tumors (relative to metabolic rates of glucose in contralateral regions of the brain) were correlated significantly with maximum lactate concentrations (relative to N-acetyl aspartate peaks in the contralateral part of the brain). In 8 tumors, no lactate was detected, and in 7 of these the maximum glucose metabolic rate was below the median value. The tumor with the highest lactate concentration also had the highest glucose metabolic rate. The topographic relation between glucose metabolic rate and lactate concentration could be analyzed in 9 patients by three-dimensional alignment of the PET and MRS images. In that analysis, maximum lactate concentrations were often not found in the same location as maximum glucose metabolism, but lactate tended to accumulate in tumor cysts, necrotic areas, and the vicinity of the lateral ventricles. The combination of FDG PET and 1H-MRS imaging demonstrates details of the spatial relation between the two poles of nonoxidative glycolysis, glucose uptake and lactate deposition.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma.J Nucl Med. 1996 Mar;37(3):457-62. J Nucl Med. 1996. PMID: 8772644
-
[Metabolic imaging to follow stereotactic radiation of gliomas -- the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT].Rofo. 2004 Aug;176(8):1114-21. doi: 10.1055/s-2004-813194. Rofo. 2004. PMID: 15346287 German.
-
Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors.J Nucl Med. 1990 Mar;31(3):302-10. J Nucl Med. 1990. PMID: 2308001
-
Multimodality assessment of brain tumors and tumor recurrence.J Nucl Med. 2011 Oct;52(10):1585-600. doi: 10.2967/jnumed.110.084210. Epub 2011 Aug 12. J Nucl Med. 2011. PMID: 21840931 Review.
-
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) of brain tumors.Neurol Clin. 1991 May;9(2):287-305. Neurol Clin. 1991. PMID: 1944100 Review.
Cited by
-
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.Br J Radiol. 2011 Dec;84 Spec No 2(Spec Iss 2):S179-95. doi: 10.1259/bjr/76389842. Br J Radiol. 2011. PMID: 22433828 Free PMC article. Review.
-
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.Neuro Oncol. 2005 Oct;7(4):465-75. doi: 10.1215/S1152851705000025. Neuro Oncol. 2005. PMID: 16212811 Free PMC article.
-
Implementation of 3 T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients.Ann Biomed Eng. 2011 Jan;39(1):193-204. doi: 10.1007/s10439-010-0128-x. Epub 2010 Jul 23. Ann Biomed Eng. 2011. PMID: 20652745 Free PMC article.
-
Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.BMC Cancer. 2018 Feb 8;18(1):167. doi: 10.1186/s12885-018-4040-3. BMC Cancer. 2018. PMID: 29422017 Free PMC article.
-
The potential of PET/MR for brain imaging.Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S105-12. doi: 10.1007/s00259-008-0962-3. Eur J Nucl Med Mol Imaging. 2009. PMID: 19104801 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical